Shuyi Mu
Key Laboratory Of Structure Based Drug Design And Discovery, 103 Wenhua Road, Shenhe District
Shenyang, 110016, China
Shenyang, 110016, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Discovery of ZSL-M028: A Potent, Selective and Orally Available Quinazoline-Based PLK4 Inhibitor Targeting TRIM37-Amplified Neuroblastoma.
Journal: Journal of medicinal chemistry
Published: July 16, 2026
Design, Synthesis, and Biological Activity Evaluation of Quinazoline-Based PLK4 Inhibitors.
Journal: Biomedicines
Published: June 08, 2026
Rational design of CZL-S092: A novel indazole-based PLK4 inhibitor targeting neuroblastoma through virtual screening and fragment-based drug design strategies.
Journal: European journal of medicinal chemistry
Published: April 27, 2025
Design, synthesis, and biological evaluation of novel N-(1H-indazol-6-yl)benzenesulfonamide derivatives as potent PLK4 inhibitors.
Journal: RSC medicinal chemistry
Published: March 21, 2025
Design, synthesis, and biological evaluation of novel pyrimidin-2-amine derivatives as potent PLK4 inhibitors.
Journal: RSC medicinal chemistry
Published: June 09, 2023
Discovery of the First Potent, Selective, and In Vivo Efficacious Polo-like Kinase 4 Proteolysis Targeting Chimera Degrader for the Treatment of TRIM37-Amplified Breast Cancer.
Journal: Journal of medicinal chemistry
Published: June 06, 2023
Discovery of CZS-241: A Potent, Selective, and Orally Available Polo-Like Kinase 4 Inhibitor for the Treatment of Chronic Myeloid Leukemia.
Journal: Journal of medicinal chemistry
Published: February 03, 2023
Showing 1-8 of 8
Last Updated: 09/26/2026